Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013, the event has nurtured a community of people from the world of life science, and created a unique place to do business. Most attendees express their delight in the informal atmosphere, combined with an organised approach to meeting highly relevant people. Return visitors come back because they feel they belong to our growing community.
Join EVERSANA’s Mike Ryan, Executive Vice President, Europe during Super Session 3 on 28 September, 16:00-17:00 – Vaccine Crosslinks: From Cancer to COVID.
Immune links between cancer and infectious diseases have long been evident, and have created the foundation for preventive, treatment-based, and tumor-specific cancer vaccines using technology originally positioned for infectious diseases. Likewise, since the start of the COVID-19 pandemic, companies globally have pivoted and reassigned their R&D and, as a result, we now have numerous breakthroughs, technology applications, and success stories of mRNA COVID-19 vaccines originating from the oncology space.
The ability for our industry to rapidly come together during a pandemic, across sectors, indications, and stages has shown that, big or small, the mutual need for one another exists. How do we continue to build a future of mutually stimulating approaches to infectious disease, immunology, oncology, and technology? We do this by connecting experts, by working to jointly to increase overall understanding of immune modulation and response, and by using technology such as ML / AI to identify and prioritize the selection antigenic determinants. We do this through collaboration.
Norway has proven to be leader in oncology, immunology – and in both answering today’s pandemic needs, as well as working towards the possible pandemics of tomorrow. In this session, our Norwegian partners will lead the discussion on where this road is headed: what can we expect, what do we need, and how can we collaborate for the best possible outcomes?
